LMAT Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 12.41%. LeMaitre Vascular's return on equity of 13.81% beat Boston Scientific's return on equity of 8.96%.

LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 19%. Given that LeMaitre Vascular has higher upside potential than Boston Scientific, analysts believe LeMaitre Vascular is more attractive than Boston Scientific.

LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Boston Scientific quarterly revenues of $4.6B. LeMaitre Vascular's net income of $11.2M is lower than Boston Scientific's net income of $566M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Boston Scientific's PE ratio is 77.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 8.62x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 4.03%. LeMaitre Vascular's return on equity of 13.81% beat Globus Medical's return on equity of 2.56%.

LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Globus Medical has an analysts' consensus of $98.69 which suggests that it could grow by 38.93%. Given that Globus Medical has higher upside potential than LeMaitre Vascular, analysts believe Globus Medical is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.608%.

LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Globus Medical quarterly revenues of $657.3M. LeMaitre Vascular's net income of $11.2M is lower than Globus Medical's net income of $26.5M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Globus Medical's PE ratio is 94.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 3.88x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 7.87%. LeMaitre Vascular's return on equity of 13.81% beat Merit Medical Systems's return on equity of 9.36%.

LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Merit Medical Systems has an analysts' consensus of $118.20 which suggests that it could grow by 19.47%. Given that LeMaitre Vascular has higher upside potential than Merit Medical Systems, analysts believe LeMaitre Vascular is more attractive than Merit Medical Systems.

LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.607%.

LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Merit Medical Systems quarterly revenues of $355.2M. LeMaitre Vascular's net income of $11.2M is lower than Merit Medical Systems's net income of $27.9M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Merit Medical Systems's PE ratio is 48.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 4.33x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 16.85%. LeMaitre Vascular's return on equity of 13.81% beat Insulet's return on equity of 43.11%.

LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 22.95%. Given that LeMaitre Vascular has higher upside potential than Insulet, analysts believe LeMaitre Vascular is more attractive than Insulet.

LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Insulet quarterly revenues of $597.5M. LeMaitre Vascular's net income of $11.2M is lower than Insulet's net income of $100.7M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Insulet's PE ratio is 44.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 9.11x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.